Skip to main content
Premium Trial:

Request an Annual Quote

Evotec Tech Establishes US Base with UC, Cincinnati Hospital Drug-Screening Deal

NEW YORK, April 4 (GenomeWeb News) - Evotec said today that it will partner with the University of Cincinnati and Cincinnati Children's Hospital to screen drug targets and cells against chemical compounds.

 

As part of the agreement, Cincinnati's Computational Medicine Center has purchased from Evotec Technologies a $2.8-million ultra-high-throughput screening system, including cellular imaging components. The CMC is a  research collaboration between UC and Cincinnati Children's Hospital that is funded by Ohio Third Frontier and the National Institutes of Health.

 

The screening system will be housed at UC's Genome Research Institute, and will serve as a core facility for UC, Cincinnati Children's, and eventually other Ohio-based researchers, Evotec said.

 

Evotec, based in Hamburg, Germany, also said that it will establish US operations for its Evotec Technologies unit in Cincinnati to support the project. Evotec Technologies is the tools division of drug-discovery firm Evotec, and markets ultra-high-throughput screening systems, as well as confocal high-content imaging systems and cell-handling devices.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.